ATE406946T1 - Verfahren zur verfestigung, bei welchem ein anti- lösungsmittel benutzt wird - Google Patents

Verfahren zur verfestigung, bei welchem ein anti- lösungsmittel benutzt wird

Info

Publication number
ATE406946T1
ATE406946T1 AT04729890T AT04729890T ATE406946T1 AT E406946 T1 ATE406946 T1 AT E406946T1 AT 04729890 T AT04729890 T AT 04729890T AT 04729890 T AT04729890 T AT 04729890T AT E406946 T1 ATE406946 T1 AT E406946T1
Authority
AT
Austria
Prior art keywords
solidification
solvent
Prior art date
Application number
AT04729890T
Other languages
English (en)
Inventor
Wridzer Bakker
Robert Geertman
Marianne Reedijk
Jozef Baltussen
Gerrald Bargeman
Lare Cornelis Van
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33418418&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE406946(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Organon Nv filed Critical Organon Nv
Application granted granted Critical
Publication of ATE406946T1 publication Critical patent/ATE406946T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/0063—Control or regulation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • B01D9/0054—Use of anti-solvent
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01D—COMPOUNDS OF ALKALI METALS, i.e. LITHIUM, SODIUM, POTASSIUM, RUBIDIUM, CAESIUM, OR FRANCIUM
    • C01D3/00—Halides of sodium, potassium or alkali metals in general
    • C01D3/22—Preparation in the form of granules, pieces, or other shaped products
    • C01D3/24—Influencing the crystallisation process
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Glanulating (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Colloid Chemistry (AREA)
AT04729890T 2003-04-29 2004-04-28 Verfahren zur verfestigung, bei welchem ein anti- lösungsmittel benutzt wird ATE406946T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46676103P 2003-04-29 2003-04-29

Publications (1)

Publication Number Publication Date
ATE406946T1 true ATE406946T1 (de) 2008-09-15

Family

ID=33418418

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04729890T ATE406946T1 (de) 2003-04-29 2004-04-28 Verfahren zur verfestigung, bei welchem ein anti- lösungsmittel benutzt wird

Country Status (22)

Country Link
US (4) US20060182808A1 (de)
EP (1) EP1620193B1 (de)
JP (1) JP5207432B2 (de)
KR (1) KR20060006949A (de)
CN (1) CN100434133C (de)
AR (1) AR044140A1 (de)
AT (1) ATE406946T1 (de)
AU (1) AU2004234057A1 (de)
BR (1) BRPI0409860A (de)
CA (1) CA2523883C (de)
CL (1) CL2004000912A1 (de)
DE (1) DE602004016311D1 (de)
ES (1) ES2312996T3 (de)
IL (1) IL171613A (de)
MX (1) MXPA05011626A (de)
MY (1) MY141189A (de)
NO (1) NO20055607D0 (de)
NZ (1) NZ543772A (de)
RU (1) RU2339364C2 (de)
TW (1) TW200500095A (de)
WO (1) WO2004096405A1 (de)
ZA (1) ZA200509597B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101262846A (zh) * 2005-07-15 2008-09-10 Map药物公司 在离散的吸入粒子中结合的多种活性药物成分及其制剂
AU2006272438B2 (en) * 2005-07-15 2011-08-04 Map Pharmaceuticals, Inc. Method of particle formation
US7942990B2 (en) 2006-12-18 2011-05-17 Daicel Chemical Industries, Ltd. Hybrid inflator
MX2009007834A (es) * 2007-01-22 2009-09-10 Cargill Inc Metodo para producir composiciones de rebaudiosido a purificado usando cristalizacion en solvente/ antisolvente.
GB0705159D0 (en) * 2007-03-19 2007-04-25 Prosonix Ltd Process for making crystals
FI120527B (fi) * 2007-06-18 2009-11-30 Crisolteq Oy Talteenottomenetelmä
GB0711680D0 (en) * 2007-06-18 2007-07-25 Prosonix Ltd Process
US20100291221A1 (en) * 2009-05-15 2010-11-18 Robert Owen Cook Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
TWI466709B (zh) * 2011-07-20 2015-01-01 Nat Univ Chung Hsing From the original berry Wolfberry a liquid - liquid freezing method for separation of high purity theaflavins palmitate Maize
EP2782584B1 (de) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natürliche kombinierte hormonersatzformulierungen und -therapien
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9452930B2 (en) * 2013-11-04 2016-09-27 New Jersey Institute Of Technology System and method for continuous polymer coating of particles
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
PT108368B (pt) 2015-03-31 2018-11-05 Hovione Farm S A Produção contínua de partículas
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
CN106853295A (zh) * 2015-12-09 2017-06-16 北大方正集团有限公司 一种基于膜分散的结晶方法
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
US10881123B2 (en) 2017-10-27 2021-01-05 Frito-Lay North America, Inc. Crystal morphology for sodium reduction
WO2019239550A1 (ja) * 2018-06-14 2019-12-19 日揮株式会社 晶析装置及び晶析方法
CN119679728A (zh) * 2018-12-28 2025-03-25 四川科伦药物研究院有限公司 制备黄体酮颗粒物的方法、所得黄体酮颗粒物及其注射剂
CN111234431A (zh) * 2020-03-31 2020-06-05 宁夏颐星新材料科技有限公司 一种消泡型聚乙烯醇粉末的生产工艺
GB202004824D0 (en) 2020-04-01 2020-05-13 Naturbeads Ltd Biopolymer particle preparation
GB202011836D0 (en) 2020-07-30 2020-09-16 Micropore Tech Limited Crystallisation methods
CN115777906A (zh) * 2021-09-10 2023-03-14 吉林大学 氯化钠纳微米粒子及其制备方法和应用
EP4637720A1 (de) 2022-12-22 2025-10-29 Nanomi B.V. Verfahren zur herstellung stabiler nanopartikel und zusammensetzung davon
CN117942426B (zh) * 2024-03-22 2024-05-31 四川大学 一种具有取向孔道结构的多级多孔材料及其制备方法和应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2716453B1 (fr) * 1994-02-22 1996-03-29 Rhone Poulenc Agrochimie Procédé de sulfinylation de composés hétérocycliques.
US4089843A (en) * 1976-09-20 1978-05-16 The Upjohn Company Precipitating polymers in powder form
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US4783484A (en) * 1984-10-05 1988-11-08 University Of Rochester Particulate composition and use thereof as antimicrobial agent
JPH0672528B2 (ja) * 1985-07-16 1994-09-14 三信工業株式会社 船舶のエンジン
RU2026670C1 (ru) * 1988-10-05 1995-01-20 Дзе Апджон Компани Способ получения тонкодисперсного твердого фармацевтического вещества
US5269926A (en) * 1991-09-09 1993-12-14 Wisconsin Alumni Research Foundation Supported microporous ceramic membranes
FR2658498B1 (fr) * 1990-02-19 1992-05-15 Atochem Particules de chlorure de magnesium a structure tronc conique, composante catalytique supportee sur ces particules, polyolefines obtenues a partir de cette composante catalytique, procedes de fabrication de ces produits.
JP2555475B2 (ja) * 1990-10-16 1996-11-20 工業技術院長 無機質微小球体の製造方法
JP2816597B2 (ja) * 1990-11-28 1998-10-27 富士写真フイルム株式会社 溶液の均一混合装置および弾性体多孔膜
IE71202B1 (en) * 1990-12-17 1997-02-12 Akzo Nv Progestagen-only contraceptive
WO1993000156A1 (fr) * 1991-06-29 1993-01-07 Miyazaki-Ken Emulsions monodispersees simples et doubles et procede de production
SG43179A1 (en) * 1991-12-18 1997-10-17 Warner Lambert Co A process for the prepatation of a solid dispersion
DK95093D0 (da) * 1993-08-20 1993-08-20 Novo Nordisk As Farmaceutisk formulering indeholdende et hormon
NZ276277A (en) * 1993-11-08 1998-04-27 Gillette Co Antiperspirant compound, in aerogel form, being an aluminium salt, a zirconium salt or an aluminium-zirconium salt
JP3492787B2 (ja) * 1994-04-15 2004-02-03 信越化学工業株式会社 固形製剤のコーティング用水性エマルジョンの濃縮方法
US6387399B1 (en) * 1994-12-02 2002-05-14 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Microencapsulated bioactive agents and method of making
SE9501384D0 (sv) * 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
US5876480A (en) * 1996-02-20 1999-03-02 The United States Of America As Represented By The Secretary Of The Navy Synthesis of unagglomerated metal nano-particles at membrane interfaces
GB9610955D0 (en) * 1996-05-24 1996-07-31 Hercules Inc Sizing composition
IL123984A (en) * 1997-04-22 2004-09-27 Akzo Nobel Nv Pharmacological dosage units containing tibolone and carrier pharmacy are acceptable
US5879715A (en) * 1997-09-02 1999-03-09 Ceramem Corporation Process and system for production of inorganic nanoparticles
ES2272066T3 (es) * 1998-04-09 2007-04-16 F. Hoffmann-La Roche Ag Proceso para la manufactura de particulas con tamaño de (sub)micras por disolucion de gas comprimido y surfactantes.
SE9801287D0 (sv) * 1998-04-14 1998-04-14 Astra Ab Incorporation of active substances in carrier matrixes
US6113795A (en) * 1998-11-17 2000-09-05 The University Of Kansas Process and apparatus for size selective separation of micro- and nano-particles
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
IN191236B (de) * 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
US6780507B2 (en) * 2000-02-09 2004-08-24 Analytical Research Systems, Inc. Hydrocapsules and method of preparation thereof
US6623761B2 (en) * 2000-12-22 2003-09-23 Hassan Emadeldin M. Method of making nanoparticles of substantially water insoluble materials
GB0102075D0 (en) * 2001-01-26 2001-03-14 Astrazeneca Ab Process
WO2003032951A1 (en) * 2001-08-29 2003-04-24 Dow Global Technologies Inc. A process for preparing crystalline drug particles by means of precipitation
CA2462338C (en) * 2001-10-10 2011-04-19 Boehringer Ingelheim Pharmaceuticals, Inc. Powder processing with pressurized gaseous fluids
US6890592B2 (en) * 2002-03-13 2005-05-10 Appleton Papers Inc. Uniform microcapsules
US6966990B2 (en) * 2002-10-11 2005-11-22 Ferro Corporation Composite particles and method for preparing

Also Published As

Publication number Publication date
ZA200509597B (en) 2006-12-27
CN1780670A (zh) 2006-05-31
TW200500095A (en) 2005-01-01
CL2004000912A1 (es) 2005-02-04
IL171613A (en) 2010-02-17
US20130131029A1 (en) 2013-05-23
US20120232296A1 (en) 2012-09-13
KR20060006949A (ko) 2006-01-20
RU2005136983A (ru) 2006-03-20
CN100434133C (zh) 2008-11-19
EP1620193A1 (de) 2006-02-01
NO20055607L (no) 2005-11-28
CA2523883C (en) 2012-01-03
US20110268806A1 (en) 2011-11-03
CA2523883A1 (en) 2004-11-11
AR044140A1 (es) 2005-08-24
AU2004234057A1 (en) 2004-11-11
MXPA05011626A (es) 2006-01-23
WO2004096405A1 (en) 2004-11-11
NZ543772A (en) 2009-05-31
EP1620193B1 (de) 2008-09-03
MY141189A (en) 2010-03-31
JP5207432B2 (ja) 2013-06-12
JP2006524565A (ja) 2006-11-02
NO20055607D0 (no) 2005-11-28
RU2339364C2 (ru) 2008-11-27
ES2312996T3 (es) 2009-03-01
HK1088268A1 (en) 2006-11-03
BRPI0409860A (pt) 2006-05-16
DE602004016311D1 (de) 2008-10-16
US20060182808A1 (en) 2006-08-17

Similar Documents

Publication Publication Date Title
DE602004016311D1 (de) Verfahren zur verfestigung, bei welchem ein anti-lösungsmittel benutzt wird
ATE340819T1 (de) Verfahren zur herstellung von polyamiden
ATE524393T1 (de) Verfahren zur zubereitung von getränken
DE602004014575D1 (de) Ein Verfahren zur Herstellung von verbesserten Rollflächen
ATE376997T1 (de) Verfahren zur herstellung von 1,4- diphenylazetidinon-derivaten
DE602004022134D1 (de) Verfahren zur herstellung von dinitrilen
DE502004001492D1 (de) Verfahren zur drehzahl-regelung
ATE431339T1 (de) Verfahren zur herstellung von n-amino- substituierten heterocyclischen verbindungen
DE50303611D1 (de) Verfahren zur herstellung von polyisobuten
DE602004007593D1 (de) Verfahren zur adaptiven Filterung
ATE466843T1 (de) Verfahren zur herstellung von n-piperidino-1,5- diphenylpyrazol-3-carboxamid-derivaten
ATE394369T1 (de) Verfahren zur aufreinigung von mesotrion
ATE402138T1 (de) Verfahren zur herstellung von 2- aminoindanderivaten
DE60336173D1 (de) Verfahren zur herstellung von vanadylpyrophosphat-katalysatoren
ATE352573T1 (de) Verfahren zur herstellung von copolymerisaten
ATE471941T1 (de) Verfahren zur herstellung von thiazolopyrimidinen
ATE377617T1 (de) Verfahren zur steigerung der festphasenpolymerisationsgeschwindigkeit
ATE382621T1 (de) Verfahren zur herstellung von nevirapin
DE50205563D1 (de) Verfahren zur Fahrzeugsteuerung
DE60328693D1 (de) Verfahren zur oxadimierung von carbonylverbindungen
DE50307674D1 (de) Verfahren zur auslösung von rückhaltemitteln
ATE468323T1 (de) Verfahren zur hertellung von 2-cyan-3-hydroxy-n- (phenyl)but-2-enamiden
DE50308383D1 (de) Verfahren zur bereitstellung von verkehrzustandsdaten
ATE322478T1 (de) Verfahren zur reinigung von caprolactam
ATE477244T1 (de) Verfahren zur herstellung von bengamide-derivaten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties